恶性胶质瘤切除后开放脑室系统植入卡莫司汀 wafer 的安全性评估
两组术后不良事件发生率(27.3% vs 23.8%,p=0.13)及随访 KPS(p=0.18)无显著差异,开放脑室系统未增加术后不良事件。
要点
- 开放脑室系统后妥善封闭缺损,可安全植入卡莫司汀 wafer。
- 开放与完整脑室系统组术后不良事件发生率无显著差异(p=0.13)。
- 随访 KPS 两组无显著差异(p=0.18)。
核心结论
- 恶性胶质瘤切除时开放脑室系统,经胶原海绵封闭后植入卡莫司汀 wafer 不增加术后不良事件。
研究设计与样本
- 脑室开放组 33 例,术中用纤维蛋白原和凝血酶包覆的胶原海绵封闭脑室壁缺损。
- 脑室完整组 21 例。
主要发现
- 两组在年龄、原发/复发胶质瘤比例、术前 KPS、全切除率及植入 wafer 数量方面具有可比性。
- 术后不良事件:开放组 9/33(27.3%),完整组 5/21(23.8%),p=0.13。
- 随访 KPS 两组无显著差异(p=0.18)。
- 开放脑室系统与术后不良事件发生率升高无关(p=0.98)。
关键数值与推荐
- 脑室开放组术后不良事件发生率 27.3%(9/33),脑室完整组 23.8%(5/21),p=0.13。
- 随访 KPS 组间比较 p=0.18。
- 开放脑室系统与术后不良事件关联分析 p=0.98。
临床怎么用
- 恶性胶质瘤切除中若开放脑室系统,可用纤维蛋白原/凝血酶包覆的胶原海绵封闭缺损后植入卡莫司汀 wafer。
- 该操作未显示增加术后不良事件风险,但需结合患者具体情况个体化决策。
局限性
- 非随机对照设计,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Implantation of biodegradable Carmustine wafers in patients with malignant glioma is not generally recommended when the ventricular system is opened during tumor resection. Thrombin/fibrinogenn-covered collagen fleeces showed promising results in sufficiently closing ventricular defects. The aim of this study was to evaluate the postoperative morbidity in patients with implanted Carmustine wafers either with opened or intact ventricular system. METHODS: A consecutive series of patients who underwent resection of malignant glioma with implantation of Carmustine wafers was analyzed. In case of opening of the ventricular system, the defect in the ventricle wall was sealed using a collagen sponge coated with fibrinogen and thrombin prior to the implantation of the wafers. Postoperative adverse events (AE) and Karnofsky performance status scale (KPS) at follow up were compared between both groups. RESULTS: Fifty-four patients were included. The ventricular system was opened in 33 patients and remained intact in 21 patients. Both groups were comparable in terms of age, rate of primary and recurrent glioma, preoperative KPS, rate of gross total resection and number of implanted wafers. Postoperative AEs occurred in 9/33 patients (27.3%) with opened and in 5/21 patients (23.8%) with intact ventricular system (p = 0.13). At follow-up assessments, KPS was not significantly different between both groups (p = 0.18). Opened ventricular system was not associated with a higher incidence of postoperative AEs (p = 0.98). CONCLUSION: Appropriate closure of opened ventricular system during resection of malignant glioma allows for a safe implantation of Carmustine wafers and is not associated with a higher incidence of postoperative AEs.
引用
- Bettag C, Hussein A, Sachkova A, et al. Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system. J Neurooncol. 2021. PMID: 34148163. doi:10.1007/s11060-021-03792-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。